EDMONTON, Alberta, Feb. 28, 2019 (GLOBE NEWSWIRE)
-- Radient Technologies Inc. (âRadientâ or the
âCompanyâ) (TSX Venture: RTI; OTCQX: RDDTF) has
released its financial results for the third fiscal quarter ended
December 31, 2018. The reviewed financial statements and
Managementâs Discussion & Analysis are available under the
Companyâs profile at www.SEDAR.com.
Key Highlights:
Financials:
Radientâs balance sheet remains strong, with a
cash balance of CAD $37.6M and working capital of CAD $37.4M as of
December 31, 2018. This reserve of cash will allow Radient to
execute on its previously announced physical and operational
expansions in Edmonton and Germany (summarized in greater detail
below). These facilities will be dedicated to the production of
premium grade, high-margin cannabis and hemp derived ingredients
and products.
Radientâs current total debt is CAD $10M and the Company was
granted its Standard Processing License from Health Canada on
February 1, 2019. This puts the Company in an advantageous position
as it expects to be generating revenues during the previously
announced build-out of its brand new facilities in Edmonton and
Germany (please see below for further details including estimated
annual throughputs).
Corporate
Update:
Edmonton I and Standard Processing License
from Health Canada:
On February 4, 2019, Radient announced it was granted its Standard Processing license from Health Canada, permitting the Company to begin legally extracting cannabinoids for the purpose of sale to Canadian federal license holders. The Company expects to be capable of processing cannabis at a capacity of more than 200 kg per day at its Edmonton I facility for its partners, including Aurora Cannabis Inc. (âAuroraâ) (TSX: ACB; NYSE: ACB). Radient will inform shareholders of the commencement of production for sale to its partners via press release.
Retrofitting Operation: CBD From Industrial Hemp (âEdmonton IIâ facility):
Radient announced on November 28, 2018 that it would be retrofitting a portion of its existing manufacturing facility for the processing of industrial hemp at industrial scale volumes (the âEdmonton IIâ facility). The Company previously estimated that it would be capable of processing throughputs of 1,200 kg per day of industrial hemp at this location. Radient now expects that it will be capable of processing industrial hemp at throughputs of up to 1,500 kg per day at this location. The Edmonton II facility is expected to be complete before the end of calendar 2019, at which point Radient expects to commence processing industrial hemp for its partners, including Aurora.
Edmonton III and Germany Manufacturing Facility Construction:
As previously announced on February 4, 2019 Radient has commenced foundation work on the construction of its Edmonton III facility of over 100,000 sq. ft., located on the lands adjacent to the Edmonton I and Edmonton II facilities, at 4035 101 St NW, Edmonton, Alberta. The Company expects to complete the development of Edmonton III in the second half of calendar 2020. Expected throughputs at this facility will be 1,000 kg of medical cannabis per day, and 10,000 kg of industrial hemp per day. Radient will be applying to receive EU-GMP certification for this facility.
Additionally, as previously announced on February 4, 2019 the Company has completed site selection and initial renderings for its Germany Manufacturing Facility, which upon completion (expected in the second half of calendar 2020), will be similar in size and throughput capabilities to the Edmonton III facility.
Estimated Annual Cannabis and Hemp Throughputs:
Radientâs Estimated Annual Capacity *1 | ||||
Facility | Biomass | Throughput/year (kg) | (metric tons) | Commissioned*2 |
Edmonton I | Cannabis | 56,000 | 56 | 2019 |
Edmonton II | Hemp | 420,000 | 420 | End of 2019 |
Edmonton III | Cannabis | 280,000 | 280 | Mid 2020 |
Edmonton III | Hemp | 2,800,000 | 2,800 | Mid 2020 |
Germany | Cannabis | 280,000 | 280 | Mid 2020 |
Germany | Hemp | 2,800,000 | 2,800 | Mid 2020 |
Total combined | Cannabis | 616,000 | 616 | Mid 2020 |
Total combined | Hemp | 6,020,000 | 6,020 | Mid 2020 |
*1 Managementâs best estimate based on a
280-day operational year *2 Expected commissioning timelines based on calendar year |
Natac Solutions Joint Arrangement:
On October 16, 2018, Radient announced that it had signed a binding letter of intent with global ingredient manufacturer, Grupo Natac S.L. (âNatacâ), to form a Joint Arrangement called Natac Solutions. The specific terms of the Joint Arrangement are still being finalized. The Natac Solutions brand was launched at SupplySide West on November 7, 2018.
Radient has now installed lab-scale and pilot-scale MAP⢠equipment into Natacâs development facility in Madrid, Spain. Natac Solutions is, according to its business plan, combining Radientâs patented MAP⢠technology and Natacâs expertise in the development of Full Plant Profile® premium plant-based ingredients in order to create proprietary customized extracts and ingredients for its customers.
Post-Reporting Events:
Receipt of Licenses for Analytical Testing and Research from Health Canada:
Radient is pleased to announce that it has received its licenses for Analytical Testing and Research (the âResearch Licensesâ) from Health Canada, issued under the Cannabis Act and its regulations. These Research Licenses were granted on February 8, 2019 for the Companyâs Research & Development Lab (the âLabâ), located at 8223 Roper Road, Edmonton, Alberta. These Research Licenses will replace the Labâs previously held Dealerâs License, which was administered under the Office of Controlled Substances.
These Research Licenses allow the Company to perform research and analytical testing on cannabis materials, submit research protocols for various activities, and to apply for amendments to its existing licenses through the Cannabis Tracking and License System (the âCTLSâ) to demonstrate its compliance to the Cannabis Regulations.
Stock Options Plan:
The Company announces today the grant of 1,025,000 stock options. Of these options, 250,000 were granted to a Director of the Company and the balance to management and consultants pursuant to the Companyâs Stock Option Plan. The options are exercisable for a period of five years at a price of $0.93 per share. This grant of options is subject to the approval of the TSX Venture Exchange.
About Radient
Radient Technologies provides industrial-scale manufacturing
solutions for premium natural ingredients and products. Utilizing
its patented MAP⢠extraction technology, Radient delivers superior
customer outcomes in terms of ingredient purity, yield, and cost,
and serves global market leaders in industries such as foods &
beverages, nutraceuticals, pharmaceuticals, cosmetics, and personal
care. Since 2016, Radient has expanded its offerings to enter the
cannabinoids market, using its MAP⢠platform to provide premium
ingredients that contain a full range of cannabinoid and terpene
profiles. Please visit www.radientinc.com for
more information.
SOURCE: Radient Technologies Inc.
Denis Taschuk, Chief Executive Officer, [email protected],
(780) 465-1318;
Prakash Hariharan, Chief Financial Officer,
[email protected],
(416) 561-9461
Caitlin Cheadle, Director of Communications, [email protected]
Forward Looking
Information:
This press release contains âforward-looking informationâ within
the meaning of applicable Canadian securities legislation.
Forward-looking information includes, without limitation,
statements regarding the growth of the Companyâs business
operations; the daily throughput targets of industrial hemp under
the section above titled âRetrofitting Operation: CBD From
Industrial Hemp (âEdmonton IIâ facility):â; the daily
throughput targets of medical cannabis and industrial hemp under
the section above titled âEdmonton III and Germany
Manufacturing Facility Construction:â; the annual throughput
targets for biomass under the section above titled âEstimated
Annual Cannabis and Hemp Throughputs:â; the Companyâs ability
to obtain other applicable licenses and certifications, including
the EU-GMP certification; the adequacy of the Companyâs working
capital to develop its business; the Companyâs ability to expand
its operations in Europe and Canada; the Companyâs ability to grow
its business in the cannabis sector; the Companyâs ability to
process cannabis and/or hemp; the timing of the commencement of
production by the Company; the Companyâs ability to retrofit and
construct facilities; the formation of the Joint Arrangement with
Natac; the impact of Natac Solutions on the Companyâs business; the
granting of stock options and the Companyâs future plans.
Generally, forward-looking information can be identified by the use
of forward-looking terminology such as âplansâ, âexpectsâ or âdoes
not expectâ, âis expectedâ, âbudgetâ, âscheduledâ, âestimatesâ,
âforecastsâ, âintendsâ, âanticipatesâ or âdoes not anticipateâ, or
âbelievesâ, or variations of such words and phrases or state that
certain actions, events or results âmayâ, âcouldâ, âwouldâ, âmightâ
or âwill be takenâ, âoccurâ or âbe achievedâ. Forward-looking
information is subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, level of
activity, performance or achievements of Radient, as the case may
be, to be materially different from those expressed or implied by
such forward-looking information. Although Radient has attempted to
identify important factors that could cause actual results to
differ materially from those contained in forward-looking
information, there may be other factors that cause results not to
be as anticipated, estimated or intended. There can be no assurance
that such information will prove to be accurate, as actual results
and future events could differ materially from those anticipated in
such statements. Accordingly, readers should not place undue
reliance on forward-looking information. Radient does not undertake
to update any forward-looking information, except in accordance
with applicable securities laws.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.